Sage’s Biogen-Partnered Essential Tremor Drug Fails In Phase II

Companies Discontinue Development In ET

For Sage, the mid-stage failure of SAGE-324 in essential tremor is its second setback in a year full of clinical trial readouts. For Biogen, it highlights a lack of later-stage pipeline prospects.

Uncontrollable hand or another parts of body. Slowness of movement or stiffness of the limbs and trunk. — The companies are evaluating indications beyond essential tremor • Source: Shutterstock

Sage Therapeutics, Inc. and partner Biogen, Inc. revealed on 24 July that SAGE-324, a positive allosteric modulator (PAM) of the GABA-A receptor, did not meet the primary endpoint in a Phase II dose-ranging study in essential tremor (ET). The clinical trial failure is Sage’s second mid-stage upset this year and the setback eliminates a needed later-stage program from Biogen’s pipeline.

Key Takeaways

Sage and Biogen will discontinue development of SAGE-324 in essential tremor after all doses of the drug failed on the primary endpoint in the Phase II...

The companies said they will end development of SAGE-324 in ET while evaluating next steps in other potential indications. Analysts said in same-day notes that they viewed the Phase II...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.